Castle Biosciences (CSTL) Stock

Here, we present four stocks, CSTL, QFIN, ESEA and STRA, with solid net profit margins that can contribute toward making a strong portfolio.

The average of price targets set by Wall Street analysts indicates a potential upside of 42% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

These five small-cap stocks show great potential for growth in 2025. They are: TALK, RYAM, CSTL, PBAM, and RSSS.

Castle Biosciences, Inc. (NASDAQ:CSTL ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded.

Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago.

Castle Biosciences (CSTL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ACG2024--New data at ACG 2024 demonstrates ability of TissueCypher to significantly reduce healthcare costs associated with management of Barrett's esophagus.

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announces that its executive management is scheduled to present a company overview at three investor conferences in November.

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.